Proof-of-concept HCV study yields promising results for a 4-week ultra-short, response-guided therapy treatment. Retrospective modeling of viral kinetics underscores the potential usefulness of a personalized modeling-based RGT approach to shorten the duration of treatment.
Therapy combination prevents HCV infection in organ transplant recipient. Anti-viral treatment optimization results in milestone achievement in collaboration with Canadian cohort. For the patient, this results in cheaper, safer treatments, and removes the added risk of HCV while in post-transplant recovery [AASLD]. This comes at a time when HCV infection and mortality rates in younger populations are on the rise due to the ongoing opioid crisis [CDC].
Mathematical modeling leads to new insights in HBV/HDV research with biopharma firm Replicor. Defining Mode of Action helped unlock promising new therapy in development for HBV treatment as well as in patients coinfected with HDV.
Success in real-time patient therapy to be tested in larger HCV treatment clinical trial with Israeli research partners. Significant implications for healthcare cost, duration of treatment and patient-care. Harel Dahari's recent work was acknowledge at a conference in South Korea.